Metropolis Healthcare Limited Stock

Equities

METROPOLIS

INE112L01020

Healthcare Facilities & Services

End-of-day quote NSE India S.E. 06:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
1,868 INR +0.95% Intraday chart for Metropolis Healthcare Limited +8.92% +11.31%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 11.89B 142M Sales 2025 * 13.56B 162M Capitalization 95.69B 1.15B
Net income 2024 * 1.34B 15.99M Net income 2025 * 1.82B 21.85M EV / Sales 2024 * 7.94 x
Net cash position 2024 * 1.29B 15.44M Net cash position 2025 * 2.27B 27.14M EV / Sales 2025 * 6.89 x
P/E ratio 2024 *
70.8 x
P/E ratio 2025 *
52.2 x
Employees 4,300
Yield 2024 *
0.52%
Yield 2025 *
0.69%
Free-Float 50.33%
More Fundamentals * Assessed data
Dynamic Chart
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand RE
Metropolis Healthcare Books 10% Increase in Fiscal Q4 Overall Revenue MT
Metropolis Healthcare Limited Announces Consolidated Revenue Results for the Fourth Quarter Ended March 31, 2024 CI
Metropolis Healthcare's Consolidated Net Profit Declines in Fiscal Q3 MT
Transcript : Metropolis Healthcare Limited, Q3 2024 Earnings Call, Feb 05, 2024
Metropolis Healthcare Limited Announces Management Changes CI
Metropolis Healthcare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests RE
Transcript : Metropolis Healthcare Limited, Q2 2024 Earnings Call, Nov 06, 2023
Metropolis Healthcare Limited Approves and Declares Payment of an Interim Dividend for the Financial Year 2023-24 CI
Crisil Keeps AA- Rating on Metropolis Healthcare's Bank Loans; Revises Outlook to Stable MT
Metropolis Healthcare Limited Announces the Cessation of Milind Sarwate as an Independent Director, Chairman/Member of Audit Committee, Risk Management Committee and Corporate Social Responsibility Committee, Effective September 06, 2023 CI
Metropolis Healthcare Limited Appoints Mohan Menon as Chief Marketing Officer CI
Metropolis Healthcare's Consolidated Profit Drops in Fiscal Q1 MT
Metropolis Healthcare to Seek Smaller Bolt-On Acquisitions CI
More news
1 day+0.95%
1 week+8.92%
Current month+2.76%
1 month+6.95%
3 months+4.59%
6 months+16.25%
Current year+11.31%
More quotes
1 week
1 715.90
Extreme 1715.9
1 887.55
1 month
1 671.60
Extreme 1671.6
1 887.55
Current year
1 450.00
Extreme 1450
1 933.50
1 year
1 209.25
Extreme 1209.25
1 933.50
3 years
1 171.35
Extreme 1171.35
3 579.90
5 years
919.00
Extreme 919
3 579.90
10 years
907.00
Extreme 907
3 579.90
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-01-01
Director of Finance/CFO - 19-11-10
President - 87-06-30
Members of the board TitleAgeSince
Director/Board Member 69 20-05-13
Director/Board Member 44 07-12-31
Director/Board Member 58 17-12-31
More insiders
Date Price Change Volume
24-05-16 1,868 +0.95% 287,646
24-05-15 1,850 +0.77% 187,622
24-05-14 1,836 +0.28% 182,332
24-05-13 1,831 +4.76% 721,361
24-05-10 1,748 +1.92% 183,992

End-of-day quote NSE India S.E., May 15, 2024

More quotes
Metropolis Healthcare Limited is an India-based company, which is engaged in providing diagnostic services. The Company operates through the pathology services segment. The Company offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. The Company also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The Company offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. It owns a chain of diagnostic centers across India, South Asia, Africa, and the Middle East. The Company has spread its footprint across 20 Indian states and over 220 cities.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
1,868 INR
Average target price
1,733 INR
Spread / Average Target
-7.24%
Consensus
  1. Stock Market
  2. Equities
  3. METROPOLIS Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW